论文部分内容阅读
目的:观察曲普瑞林治疗女童特发性中枢性性早熟(ICPP)的临床疗效,为ICPP的临床治疗提供依据。方法:应用曲普瑞林对29例ICPP女童进行治疗,观察治疗前与治疗后的第二性征、卵巢发育情况、血清雌二醇(E2)、垂体促性腺素浓度、骨龄(BA)、生长速率(GV)及身高(PAH)等的变化。结果:治疗后患儿乳房、卵巢体积均有缩小;E2、促黄体生成激素(LH)及卵泡刺激素(FSH)峰值均显著降低;骨龄成熟延迟,骨龄/实际生活年龄(BA/CA)值下降;治疗前预测成人终身高为(155.5±0.61)cm,治疗12个月后为(159.1±0.81)cm,治疗后较治疗前有明显改善,差异具有统计学意义(P<0.01)。结论:曲普瑞林治疗ICPP效果显著,能有效抑制性腺轴及性腺的发育和骨龄的增长,改善成年身高。
Objective: To observe the clinical efficacy of triptorelin in the treatment of idiopathic central precocious puberty (ICPP) in girls and provide the basis for the clinical treatment of ICPP. Methods: Twenty - nine ICPP girls were treated with triptorelin. The second sexual characteristics, ovarian development, serum estradiol (E2), pituitary gonadotropin (BA), bone age (BA) Growth rate (GV) and height (PAH) and other changes. Results: The breast and ovary volume of the children decreased after treatment. E2, the peak of luteinizing hormone (LH) and follicle stimulating hormone (FSH) were significantly decreased, the maturation of skeletal age was delayed, and the bone age / actual age of life (155.5 ± 0.61) cm before treatment, and (159.1 ± 0.81) cm after 12 months of treatment. There was a significant difference between before and after treatment (P <0.01). Conclusion: Triptorelin treatment of ICPP significant effect, can effectively inhibit the gonadal axis and gonadal development and growth of bone age, improve adult height.